Back close

COVID-19 and diabetes: What do we know so far?

Publication Type : Journal Article

Publisher : SAGE Publications

Source : Experimental Biology and Medicine Volume 247 Issue 15 Pages 1330-1334

Url :

Campus : Coimbatore

School : School of Physical Sciences

Year : 2022

Abstract : Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.

Cite this Research Publication : Prakash Gangadaran, Himabindu Padinjarathil, Shri Hari Subhashri Rajendran, Manasi P Jogalekar, Chae Moon Hong, Baladhandapani Aruchamy, Uma Maheswari Rajendran, Sridharan Gurunagarajan, Anand Krishnan, Prasanna Ramani, Kavimani Subramanian, "COVID-19 and diabetes: What do we know so far?", Experimental Biology and Medicine Volume 247 Issue 15 Pages 1330-1334, 2022

Admissions Apply Now